The Potential Role of Renin Angiotensin System (RAS) and Dipeptidyl Peptidase-4 (DPP-4) in COVID-19: Navigating the Uncharted by Al-Kuraishy, Hayder M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
The Potential Role of Renin 
Angiotensin System (RAS)  
and Dipeptidyl Peptidase-4  
(DPP-4) in COVID-19: Navigating 
the Uncharted
Hayder M. Al-Kuraishy, Marwa S. Al-Niemi, 
Nawar R. Hussain, Ali I. Al-Gareeb, Nasser A. Al-Harchan  
and Azhar H. Al-Kurashi
Abstract
Novel coronavirus (COVID-19) led to infected pneumonia and acute respiratory 
distress syndrome (ARDS) and acute kidney injury (AKI). The entry-point receptor 
for COVID-19 is angiotensin-converting enzyme 2 (ACE2) at lung, and dipeptidyl 
peptidase-4 (DPP-4) is a receptor for Middle East respiratory syndrome coronavi-
rus (MERS-CoV). There is 80% similarity between MERS-CoV and COVID-19. This 
study was planned to review the potential link between the incidence and severity 
of COVID-19 regarding the modulation of DPP-4 and ACE2 by DPP-4 and renin 
angiotensin system (RAS). In COVID-19, SARS-CoV2 binds ACE2 which is highly 
expressed by the epithelial cells of the blood vessel, intestine, and lung. However, 
pulmonary ACE2 seems to be a protective defense pathway during ARDS. DPP-4 is 
not concerned with the entry of COVID-19 but mediates the inflammatory reac-
tions and cytokine storm that induced ARDS and AKI by COVID-19. The interac-
tion between DPP4i and RAS inhibitors seem to augment the expression of AT2 
receptor and ACE2 which are under extensive researches to find the pathophysi-
ological pathway of COVID-19 infection. This beneficial interaction between DPP4i 
and RAS shed light for possible attenuation of COVID-19-induced ARDS and AKI 
mainly in critically ill patients with systemic hypertension.
Keywords: COVID-19, angiotensin-converting enzyme 2, dipeptidyl peptidase-4, 
acute respiratory distress syndrome, acute kidney injury
1. Introduction
Coronavirus (CoV) is a positive-sense single-strand RNA genome, which is 
the largest known RNA virus, constitutes Riboviria of Coronaviridae family and 
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Orthocoronavirinae subfamily with a genome size of 27–34 kilobases. The name 
coronavirus is derived from the Latin word corona, meaning crown or halo, which 
is the feature appearance under electron microscope. Regarding COVID-19, it is 
similar to the other RNA viruses with additional endoribonuclease and exoribo-
nuclease terminal caps (Figure 1) [1].
Formerly different researches were done to identify the cause of obscure respi-
ratory tract infections. The identified novel agents were severe acute respiratory 
syndrome coronavirus (SARS-CoV) and human coronavirus NL63 (HCoV-NL63) 
[2] CoV causes human acute respiratory infection in about 5–30% of the total 
respiratory infection. In the past, between 2002 and 2003, an epidemic had been 
shown caused by SARS-CoV, which causes severe acute respiratory syndrome in 
8000 subjects with 750 deaths. SARS-CoV is a second coronavirus group, while 
HCoV-NL63 is called group 1 coronavirus [3, 4].
On December 2019, a number of cases with a novel coronavirus (COVID-19) led 
to infected pneumonia in Wuhan in central China. Four cases with pneumonia of 
unknown etiology were reported on 29 December 2019, which heralds the similar 
outbreak of 2003 SARS-CoV [5].
At this time, no vaccines or effective antiviral agents are approved for the treat-
ment or prevention of human COVID-19. Therefore, the emergence of COVID-19 
is regarded as a priority by the World Health Organization (WHO), Center for 
Disease Control and Prevention (CDC), and health agencies for the developing a 
therapeutic effective drug against COVID-19. In general COVID-19 as other posi-
tive-sense RNA virus is characterized by high genetic plasticity and mutations due 
to short replication time, with a higher rate of recombination. These criteria limit 
and challenge for discovering novel antiviral agents [6, 7]. However, nucleotide 
and nucleoside analogue inhibitors (NIs) may be an effective agent by the reduc-
tion of genetic mapping of COVID-19 [8]. NIs such as ribavirin, remdesivir, and 
beta-D-N4-hydroxycytidine could be effective agents despite emergence of rapid 
resistance [9].
Previously, it has been reported by Li et al. [11] and Kuba et al. [10] that the 
entry-point receptor for SARS-CoV is angiotensin-converting enzyme 2 (ACE2) 
at the lung [10, 11]. Besides, Eckerle et al. reported that dipeptidyl peptidase-4 
(DPP-4) which cluster of differentiation 26 (CD26) is widely expressed on the 
surface of human cells which acts as a receptor for Middle East respiratory syn-
drome coronavirus (MERS-CoV) [12]. Since there is a 80% similarity between 
MERS-CoV and SARS-CoV with SARS-CoV-2, this study was planned to review 
Figure 1. 
Structure of SARS-CoV2.
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the potential link between the incidence and severity of COVID-19 regarding the 
modulation of DPP-4 and ACE2 by DPP-4 and renin angiotensin system (RAS) 
inhibitors, respectively.
2. Literature search strategy
In general, an endeavor of this study article was to present a mini review con-
cerning DPP-4 and RAS and their inhibitors in relation to the incidence and severity 
of COVID-19. Evidences and substantiations from experimental, preclinical, and 
clinical studies are assessed, given the nature and character of the subject area; it 
remains clear that this literature search cannot be considered as a systemic review. A 
multiplicity and array of search policy took on and are assumed, which is integrated 
by electronic database searches of Scopus, Web of Science, Medline, Cochrane 
Central Register of Controlled Trials (CCTR), and PubMed using MeSH terms, key-
words, and title words during the search. The terms used for these searches were as 
follows: COVID-19 or coronavirus or SARS-CoV-2 and DPP-4 OR renin angiotensin 
system; COVID-19 or SARS-CoV-2 and DPP-4 inhibitors or sitagliptin, vildagliptin, 
and insulin resistance; incidence of COVID-19 or coronavirus or SARS-CoV-2; and 
hypertension or orphan drugs or glucagone-like peptide 1 (GLP-1) or dipeptidyl 
peptidase-IV inhibitors (DPPIV) or thiazolidinediones (TZDs).
Reference lists of previous and recent notorious articles were reviewed. In addi-
tion, only English articles were measured, and case reports were also of concerned 
in this review. The key features of predictable and suitable search studies were 
considered, and the conclusions were summarized and summed up in a mini review.
3. Renin angiotensin system (RAS) and COVID-19
RAS is a signaling pathway for the regulation of blood pressure, blood volume, 
natriuresis, and other vascular functions [13]. RAS consists of different effector 
peptides that control the dynamic vascular functions. Angiotensinogen from the 
liver is converted to angiotensin I (AngI), which is converted to angiotensin II 
(AngII) by angiotensin-converting enzyme 1(ACE1). AngII activates two types of 
receptors which are AT1 (vasoconstrictor) 90% and AT2 (vasodilator) 10%. The 
overall effect of AngII is vasoconstriction with sympathetic activation and aldo-
sterone release. Excess of AngII is metabolized by ACE2 into vasodilator Ang (1–7) 
which act on specific receptor called MAS receptor (Figure 2). AngII can also be 
converted to angiotensin A by mononuclear leukocyte-derived aspartate decarbox-
ylase (MLDAD), leading to the formation of alamandine, which has been shown to 
bind to the mas-related G protein-coupled receptor D [14].
In COVID-19, SARS-CoV-2 binds ACE2 which is highly expressed by the 
epithelial cells of the blood vessel, intestine, and lung. The expression of ACE2 is 
augmented by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) (Figure 3) [15] as well as ibuprofen and thiazolidinedio-
nes, and cigarette smoking also increases the expression of ACE2 at epithelial cells 
of the lung. Therefore, hypertensive patients on ACEIs or ARBs are at higher risk for 
COVID-19 [16, 17].
Recently, Zhou et al. [18] found that the COVID-19 genome is 96% identical to 
the bat CoV, so spike glycoprotein (S protein) and receptor binding domain (RBD) 
of both SARS-CoV-2 and bat CoV bind ACE2, which might explain the cross-species 
transmission, which means from bat to human and from human to human [19]. In 
addition, the affinity of COVID-19-RBD to ACE2 is approximately 10–20 times more 
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than that of SARS-CoV [20]. It has been shown that smoking upregulates ACE2 
via activation of pulmonary platelet factor and induction of oxidative stress and 
inflammatory reactions. Increased ACE activity also contributes to impaired vascu-
lar relaxation observed in smokers. Irbesartan, an AT1R antagonist (also known as 
angiotensin receptor blocker), was found to reduce arterial stiffness in hypertensive 
patients. When stratified by smoking status, smokers were found to have stiffer 
arteries before treatment, and irbesartan was able to reduce arterial stiffness to 
a greater extent in smokers than in nonsmokers, indicating that overactivity of 
Figure 2. 
Renin angiotensin system (RAS).
Figure 3. 
Role of angiotensin-converting enzyme 2 (ACE2).
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the RAS contributes to increased arterial stiffness in smokers. On the other hand, 
overexpression and upregulation of ACE2 is regarded as a protective measure via 
the reduction of pro-inflammatory cytokines mainly tumor necrosis factor (TNF-α) 
which is augmented in smoker subjects [21]. Therefore, active cigarette smoking 
subjects are at high risk for COVID-19 regardless of gender difference (Figure 4).
The activity of RAS is high in the lung, which is the main source of circulat-
ing AngII due to higher expression of ACE. Lung ACE2 controls the balance of 
RAS activation through regulating AngII/Ang 1–7 ratio. Local pulmonary AngII 
provokes vascular permeability, causing pulmonary edema [22]. However, in 
acute respiratory distress syndrome (ARDS), the activation of RAS is necessary to 
maintain oxygenation since ACE2 knockout mice illustrated more sever pulmonary 
damage than the controls. Thereby, pulmonary ACE2 seems to be a protective 
defense pathway during ARDS [23]. In addition, ACE2 has an important anti-
inflammatory action, and so ACE2 therapy is effective in the treatment of hyperten-
sion and diabetic nephropathy through attenuation of AngII-induced inflammation 
and oxidative stress [24]. Even so recombinant ACE2 is effective in the management 
of animal model ARDS, the inhibition of ACE2 may lead to fatal outcomes due to 
the reduction of vasodilator Ang1–7. However, chronic intravenous administration 
of Ang1–7 or MAS agonists leads to vasodilatation independent of circulating AngII 
levels [25].
Depending on these observations, different studies illustrate that RAS inhibi-
tors might be of value in the reduction of ARDS, respiratory failure, and acute 
pneumonia that are induced by SARS-CoV-2 [26]. Though Wang [27] confirms that 
RAS inhibitors increase the risk of COVID-19 due to the upregulation of pulmonary 
ACE2, this study recommends stopping RAS inhibitors during COVID-19 outbreak. 
Nonetheless, all recruited patients with COVID-19 developed ARDS without any 
evidence of AKI [27]. Thus, RAS system mainly ACE2/Ang1–7 grows to be the focus 
and meeting point of different researches to implicate this pathway in the pathogen-
esis of COVID-19.
Guo et al. found that the expression of ACE2 is higher renal tubules than in lung 
tissues; nevertheless COVID-19 leads to ARDS in much at higher than that of acute 
Figure 4. 
Nicotine smoking and ACE2.
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kidney injury (AKI), suggesting other mechanism other than ACE2 binding in the 
pathogenesis of COVID-19 [28]. AT2 receptor is activated by ACE2 and Ang1–7 
that oppose the activity of AT1 receptor [29]. Similarly, AT2 receptors are highly 
expressed in lung epithelial cells compared with kidney tissues. Pulmonary AT2 
receptors mediate lung injury through the augmentation of pulmonary inflamma-
tion and vascular permeability as well as the development of pulmonary fibrosis 
[30]. Consequently, pulmonary AT2 receptor antagonists are regarded as a novel 
pathway in COVID-19-induced pneumonia and ARDS. This finding does not rule 
out the responsibility of ACE2, since the activation of ACE2 by SARS-CoV-2 causes 
considerable activation of pulmonary AT2 receptors (Figure 5).
Amid myriad literature survey, polymorphism of ACE2 has been associated 
with different cardio-metabolic disorders; thus, the implication of ACE2 and AT2 
receptors in COVID-19-induced pneumonia should be considerably regarded with 
ACE2 polymorphisms [31]. Furthermore, the expression of ACE2 might not be 
necessary for COVID-19 infection and viral entry, as the absence of SARS-CoV-2 
in some ACE2 expressing cell types as well; this infection was observed in some cell 
line lacking ACE2, suggesting a vague pathway, and cofactors might be necessary 
for human infection [32]. Amusingly, Gurwitz [33] animal model study shows 
that pulmonary COVID-19 infection leads to significant lung injury through the 
downregulation of ACE2, which is attenuated by the administration of ARB. This 
study suggests the protective role of RAS inhibitors in COVID-19-induced ARDS 
[33]. Indeed, most of reported data from various social media during this dangerous 
outbreak was not legitimate due to overwhelming lay press and sparked concerns. 
Therefore, the high incidence of COVID-19 in patients receiving ACEIs or ARBs 
might be not because of these drugs but because those patients were often older, 
hypertensive, or diabetic which in fact increase the risk of COVID-19 infection. In 
addition, a recent clinical trial on the effectiveness of recombinant ACE2 (rACE) in 
the management of COVID-19 infection has been started [34], and we are waiting 
for these results. Thus, according to the guideline for the management of hyperten-
sion, RAS inhibitors should be used irrespective of COVID-19 infection, as sudden 
Figure 5. 
Role of AT2 receptors in COVID-19.
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withdrawal of these therapeutic regimens may increase the risk of deleterious 
outcomes in critically ill patients.
Regarding gender differences in the expression of ACE2, ACE2 gene is located 
on the X chromosome, which gives the possibility of gender differences in the 
susceptibility for COVID-19 infection. Females have lower levels of ACE2 com-
pared with males, which gives a clue of male vulnerability to COVID-19 infection as 
compared with females [35]. In addition, Shenoy et al. report that estrogen attenu-
ates AngII-induced pulmonary fibroblast proliferation due to the upregulation of 
Figure 6. 
Potential effects of endothelin-1 and aldosterone on the expression of ACE2.
Figure 7. 
Shedding of ACE2 during SARS-CoV-2 entry.
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ACE2 [36]. The expression of ACE2 is regulated by different endogenous hormones 
and peptides; both endothelin-1 and aldosterone downregulate ACE2 expression in 
a rat model. So, RAS inhibitors may improve ACE2 expression via suppression of 
endogenous endothelin-1 and aldosterone (Figure 6) [37].
Moreover, ACE2 contains ectodomain and endodomain at cytoplasmic 
membrane; the shedding part (ectodomain) is essential for the replication of 
SARS-CoV-2 (Figure 7) [38].
At the heart of the dilemma, extensive researches are recommended to explore 
the specific role of ACE2 and RAS inhibitors during precarious COVID-19 world-
wide outbreak.
4. Dipeptidyl peptidase-4 (DPP-4) and COVID-19
DPP4, also called adenosine deaminase complexing protein 2 (ADCP2) or 
adenosine deaminase binding protein (ADBP), is widely distributed on the 
surface of human cells. DPP4 is involved in the regulation of blood glucose, 
oxidative stress, inflammation, immune system, cell adhesion, and apoptosis 
[39]. The substrates of DPP4 are glucagone-like peptide 1 (GLP-1), stromal 
cell-derived factor 1 (SDF-1), brain natriuretic peptide (BNP), substance P, and 
neuropeptide Y (NPY). Furthermore, DPP4 interacts with different ligands such 
as caveolin-1, chemokine receptor type 4 (CXCR4), adenosine deaminase (ADA), 
and fibronectin [40].
DPP4 inhibitors (DPP4i) such as sitagliptin, saxagliptin, and vildagliptin are 
approved in the management of type 2 diabetes mellitus (T2DM). Additionally, 
DPP4i have a potential therapeutic effect regarding hypertension, endothelial 
dysfunction, cardioprotection, and connective tissue diseases (Figure 8) [41].
Regarding the role of DPP4 in viral entry and replication, Widagdo et al. [42] 
found that DPP4 is an important receptor for MERS-CoV transmission. DPP4 
receptors are found in the human upper respiratory tract epithelium. Lacking of 
these receptors may restrict the transmission of MERS-CoV.
S protein of MERS-CoV binds specifically to DPP4 receptors. These interactions 
provoke proteolytic activation for viral entry and fusion of viral membrane with the 
cell membrane [43].
Figure 8. 
Metabolic effects of DDP-4 inhibitors.
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It has been observed that polymorphism in DPP4 gene is concerned with 
different cardio-metabolic disorders and transmission of MERS-CoV [44]. The 
polymorphism in DPP4 reduces the interactions between S proteins of MERS-
CoV with cellular membranes. The difference in the incidence between Arabian 
and African MERS-CoV is mainly related to the genotype polymorphism of 
DPP4 [45].
Since there is a higher genomic similarity between SARS-CoV-2 and SARS-CoV, 
the implication of DPP4 as a receptor or a pathogenetic pathway in COVID-19-
induced ARDS is reasonable. In COVID-19 infection, ARDS is developed due to 
massive cytokine release (cytokine storm), due to uncontrolled systemic inflam-
matory response, and due to the release of pro-inflammatory cytokine, including 
INF-α-, IL-6, IL-12, IL-33, etc., which cause multiple organ failure [46].
It has been reported that DPP4 is highly expressed on alveolar cells (type I and 
type II), alveolar macrophage, pleural mesothelium, and vascular endothelium. 
Besides, pulmonary vascular endothelial cells (PVECs) are the main source of 
pro-inflammatory cytokines in ARDS. DPP4 is upregulated in pneumonia, asthma, 
and ARDS; therefore, DPP4 inhibitors may reduce the inflammatory reaction and 
cytokine release in acute lung injury and ARDS through immune-modulation 
effect [47].
Different studies illustrated that DPP4 inhibitors inhibit the release of IL-6 and 
TNF-α in ARDS without effect on the blood glucose when used in a small dose [48]. 
Therefore, DPP4 inhibitors might be a therapeutic option in the management of 
COVID-19-induced ARDS.
5. The interactions between RAS and DPP4 in COVID-19
DPP4 is involved in the activation of T-cell, so the activated T-cell can synthesize 
and secret AngII by local RAS. So, AngII-dependent T-cell activation is inhibited by 
DPP4i, leading to a significant reduction of endothelial inflammation and vaso-
constriction [49]. Similarly, Bengsch et al. [50] disclosed that DPP4 receptors are 
highly expressed on Th17 which induced AngII release during ARDS. High circulat-
ing AngII level leads to the activation of inflammatory reactions via activation of 
the release of IL-18, 1 L-17, IL-6, and TNF-α. These mediators are essential for the 
induction of epithelial and endothelial cell injury during ARDS. DPP4i plays an 
integral role in the attenuation of IL-6 and TNF-α and associated inflammation and 
endothelial damage [51].
Therefore, DPP4i interferes with RAS at different levels; as teneligliptin attenu-
ates AngII action, liraglutide downregulates AT1 and upregulates AT2 receptors 
during intravenous AngII infusion. Besides, exenatide inhibits the secretion of 
renin, AngII, and angiotensinogen [52].
What is more, DPP4i has a nephroprotective effect through the regulation of 
sodium and water reabsorption. Both DPP4i and GLP-1 increase sodium excretion 
through direct effect on proximal renal tubules or indirect effect via the activation 
of brain natriuretic peptide (BNP) (Figure 9) [53].
Consequently, DPP4i exerts protective effects on the lung and kidney which 
are the main tropism of COVID-19 through direct modulation of inflammatory 
reactions or indirectly through the attenuation of AngII. The interaction between 
DPP4i and RAS inhibitors seems to augment the expression of AT2 receptor 
which is under extensive researches to find the pathophysiological pathway of 
COVID-19 infection. Indeed, this interaction sheds light for possible attenuation 
of COVID-19-induced ARDS and AKI mainly in critically ill patients with systemic 
hypertension.
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6. Conclusion
ACE2 is regarded as a portal entry-point for SARS-CoV-2; however, human cell 
lines with higher expression of ACE2 are not infected by this virus. The overex-
pression of AT2 receptors by ACE2 and Ang1–7 is regarded as a novel pathway in 
COVID-19-induced pneumonia and ARDS. Females have lower levels of ACE2 than 
males, which give a clue of male vulnerability to COVID-19 infection as compared 
with females. Even so, ACE2 is regarded as a protective pathway which reduces 
COVID-19-induced acute inflammatory reactions. RAS inhibitors and DPP4i 
increase the expression of pulmonary ACE2, so the implication of RAS inhibitors 
and DPP4i as augmenters of COVID-19 is not practical. Therefore, addition of, 
DPP4i to RAS inhibitors in hypertensive patients with COVID-19 may reduce the 
risk of ARDS and AKI.
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Figure 9. 
Metabolic effects of DDP-4 inhibitors regarding obesity and insulin resistance.
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